3 Reasons to Buy the Dip With Exelixis
In just two days, Exelixis (NASDAQ: EXEL) has lost over 15% of its market cap. The tumble for the once-hot biotech stock started last week with a downgrade of the stock by an analyst at Leerink Partners. It wasn't over anything Exelixis did -- analyst Mike Schmidt said the biotech's fundamentals still appear to be strong. Instead, the concerns were about Exelixis stock's valuation.
Over the last three years, buying Exelixis stock every time it pulled back proved to be a winning strategy. Is that still the case? I think so. Here are three reasons to buy the dip with Exelixis.
Image source: Getty Images.
Source: Fool.com
Bristol-Myers Squibb Stock
€45.26
-2.070%
With 7 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
As a result the target price of 70 € shows a very positive potential of 54.66% compared to the current price of 45.26 € for Bristol-Myers Squibb.
